Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
10 août 2020 07h00 HE
|
Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
07 août 2020 07h00 HE
|
Imara, Inc.
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
30 juil. 2020 07h00 HE
|
Imara, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
12 juin 2020 07h00 HE
|
Imara, Inc.
Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of...
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
21 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports First Quarter 2020 Financial Results and Business Highlights
07 mai 2020 07h00 HE
|
Imara, Inc.
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
06 mai 2020 16h05 HE
|
Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
04 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
29 avr. 2020 16h15 HE
|
Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
23 avr. 2020 07h00 HE
|
Imara, Inc.
Industry leader with global clinical development expertise to help guide Imara’s clinical advancement Imara also announces departure of Chief Medical Officer, Willem Scheele BOSTON, April 23, 2020 ...